Publication
Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort
| dc.contributor.author | Kissling, Esther | |
| dc.contributor.author | Pozo, Francisco | |
| dc.contributor.author | Buda, Silke | |
| dc.contributor.author | Vilcu, Ana-Maria | |
| dc.contributor.author | Gherasim, Alin | |
| dc.contributor.author | Brytting, Mia | |
| dc.contributor.author | Domegan, Lisa | |
| dc.contributor.author | Gómez, Verónica | |
| dc.contributor.author | Meijer, Adam | |
| dc.contributor.author | Lazar, Mihaela | |
| dc.contributor.author | Vučina, Vesna Višekruna | |
| dc.contributor.author | Dürrwald, Ralf | |
| dc.contributor.author | van der Werf, Sylvie | |
| dc.contributor.author | Larrauri, Amparo | |
| dc.contributor.author | Enkirch, Theresa | |
| dc.contributor.author | O’Donnell, Joan | |
| dc.contributor.author | Guiomar, Raquel | |
| dc.contributor.author | Hooiveld, Mariëtte | |
| dc.contributor.author | Petrović, Goranka | |
| dc.contributor.author | Stoian, Elena | |
| dc.contributor.author | Penttinen, Pasi | |
| dc.contributor.author | Valenciano, Marta | |
| dc.contributor.author | I-MOVE primary care study team | |
| dc.date.accessioned | 2020-04-27T19:02:18Z | |
| dc.date.available | 2020-04-27T19:02:18Z | |
| dc.date.issued | 2019-11-28 | |
| dc.description | I-MOVE primary care study team (Portugal): Ana Paula Rodrigues, Ausenda Machado, Baltazar Nunes, Irina Kislaya, Inês Costa, Patrícia Conde, Paula Cristóvão, Pedro Pechirra, Vítor Borges | pt_PT |
| dc.description.abstract | Introduction: Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim: The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods: We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32–54-year-olds (1964–86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results: Influenza A(H3N2) VE among all ages was −1% (95% confidence interval (CI): −24 to 18) and 46% (95% CI: 8–68), −26% (95% CI: −66 to 4) and 20% (95% CI: −20 to 46) among 0–14, 15–64 and ≥ 65-year-olds, respectively. Among 15–64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: −34 to 50) and −74% (95% CI: −259 to 16), respectively. VE was −18% (95% CI: −140 to 41), −53% (95% CI: −131 to −2) and −12% (95% CI: −74 to 28) among 15–31-year-olds (1987–2003), 32–54-yearolds (1964–86) and 55–64-year-olds (1954–63), respectively. Discussion: The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964–86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15–64-year-olds and the public health impact of the I-REV hypothesis warrant further study. | pt_PT |
| dc.description.sponsorship | ECDC | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Euro Surveill. 2019 Nov;24(48):1900604. doi: 10.2807/1560-7917.ES.2019.24.48.1900604 | pt_PT |
| dc.identifier.doi | 10.2807/1560-7917.ES.2019.24.48.1900604 | pt_PT |
| dc.identifier.issn | 1560-7917 | |
| dc.identifier.uri | http://hdl.handle.net/10400.18/6536 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | European Centre for Disease Prevention and Control | pt_PT |
| dc.relation.publisherversion | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.48.1900604 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nd/4.0/ | pt_PT |
| dc.subject | Influenza | pt_PT |
| dc.subject | A(H3N2) | pt_PT |
| dc.subject | Imprinting | pt_PT |
| dc.subject | Determinantes de Saúde e Doença | pt_PT |
| dc.subject | Estado de Saúde e Doença | pt_PT |
| dc.subject | Gripe | pt_PT |
| dc.subject | Vacina Antigripal | pt_PT |
| dc.subject | EuroEVA | pt_PT |
| dc.subject | Efetividade | pt_PT |
| dc.subject | Época 2018-2019 | pt_PT |
| dc.title | Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 48 | pt_PT |
| oaire.citation.startPage | 1900604 | pt_PT |
| oaire.citation.title | Eurosurveillance | pt_PT |
| oaire.citation.volume | 24 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
